Company Overview of KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, develops monoclonal antibody therapeutics for the treatment of cancer in the United States. The company’s product candidates include KB004, which is in a Phase II clinical trial for the treatment of myelodysplastic syndrome and myelofibrosis; and KB003 that completed Phase II clinical trial to treat chronic myelomonocytic leukemia, an orphan oncology indication. KaloBios Pharmaceuticals, Inc. was founded in 2000 and is headquartered in South San Francisco, California.
442 Littlefield Avenue
South San Francisco, CA 94080
Founded in 2000
Key Executives for KaloBios Pharmaceuticals, Inc.
Interim Chief Executive Officer, Interim President and Chief Financial Officer
Total Annual Compensation: $340.0K
Chief Scientific Officer
Total Annual Compensation: $287.5K
Compensation as of Fiscal Year 2014.
KaloBios Pharmaceuticals, Inc. Key Developments
KaloBios Pharmaceuticals, Inc. Appoints Ronald A. Martell to the Position of Executive Chairman
May 28 15
KaloBios Pharmaceuticals, Inc. announced the appointment of Ronald A. Martell, to the position of Executive Chairman. Mr. Martell currently serves as a member of the KaloBios Board of Directors. In this new role, he will work directly with the company's senior management team to refine and execute on the strategic plan to transition KaloBios to a focused monoclonal antibody company developing therapeutics for orphan oncology indications with high unmet medical need. Mr. Martell will assume the duties of Board Chairman currently held by Ted W. Love, MD, who will continue to act as lead independent director on the KaloBios Board. Mr. Martell has more than 25 years' experience building and managing unique businesses in the biotech industry, and most recently served as Chief Executive Officer at Sevion Therapeutics, prior to which he held similar roles at NeurogesX and at Poniard Pharmaceuticals.
Kalobios Pharmaceuticals, Inc. Proposes Series of Alternate Amendments to its Amended and Restated Certificate of Incorporation
May 26 15
KaloBios Pharmaceuticals, Inc. proposed a series of alternate amendments to its amended and restated certificate of incorporation, to effect, at the discretion of the board of directors, a reverse stock split of the company's common stock, whereby each outstanding 4, 5, 6, 7, 8, 9 or 10 shares would be combined, converted and changed into one share of common stock, at its annual general meeting will be held on July 7, 2015.
KaloBios Pharmaceuticals, Inc., Annual General Meeting, Jul 07, 2015
May 26 15
KaloBios Pharmaceuticals, Inc., Annual General Meeting, Jul 07, 2015., at 10:00 Pacific Standard Time. Location: the offices of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, 1200 Seaport Blvd. Agenda: To elect the seven nominees to the board of directors to hold office until the 2016 annual meeting of stockholders; to approve a series of alternate amendments to its amended and restated certificate of incorporation, to effect, at the discretion of the board of directors, a reverse stock split of the company's common stock, whereby each outstanding 4, 5, 6, 7, 8, 9 or 10 shares would be combined, converted and changed into one share of common stock; to approve amendments to its 2012 equity incentive plan to, among other things, increase the number of shares reserved for issuance there under by 2,500,000 shares on a pre-reverse stock split basis; to ratify the appointment of Ernst & Young LLP as its independent registered public accounting firm for the year ending December 31, 2015; and to transact any other business that may properly come before the meeting.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|